N-[4-methyl-3-(1-{6-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrimidin-4-yl}-1H-benzoimidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-methyl-3-(1-{6-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrimidin-4-yl}-1H-benzoimidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide
• 英文别名: N-(4-methyl-3-(1-(6-(3-(4-methylpiperazin-1-yl)propylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide；N-[4-methyl-3-[[1-[6-[3-(4-methylpiperazin-1-yl)propylamino]pyrimidin-4-yl]benzimidazol-2-yl]amino]phenyl]-3-(trifluoromethyl)benzamide
• 化学式: C₃₄H₃₆F₃N₉O
• 分子量: 643.715
• InChiKey: FILQIUCXPQZUON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  47
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  103
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  1-(3-氨丙基)-4-甲基哌嗪 、 N-{3-[1-(6-chloro-pyrimidin-4-yl)-1H-benzoimidazol-2-ylamino]-4-methyl-phenyl}-3-trifluoromethyl-benzamide 以 异丙醇 为溶剂， 反应 1.0h， 生成 N-[4-methyl-3-(1-{6-[3-(4-methyl-piperazin-1-yl)-propylamino]-pyrimidin-4-yl}-1H-benzoimidazol-2-ylamino)-phenyl]-3-trifluoromethyl-benzamide
  参考文献：
  名称：

  Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II

  摘要：

  A series of 4-amino-6-benzimidazole-pyrimidines was designed to target lymphocyte-specific tyrosine kinase (Lck), a member of the Src-family kinases (SFKs). These type II inhibitors were optimized using a cellular Lck-dependent proliferation assay and are capable of inhibiting Lck at single-digit nanomolar concentrations. This scaffold is likely to serve a valuable template for developing potent inhibitors of a number of SFKs. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.123

文献信息

• Pyrimidine-Substituted Benzimidazole Derivatives as Protein Kinase Inhibitors
  申请人：Zhang Guobao

  公开号：US20080255112A1

  公开（公告）日：2008-10-16

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKKα, IKKβ, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SIK, Tie2, TrkB and/or WNK3 kinases.

  本发明提供了一种新型的化合物类别，包括这种化合物的药物组合物和使用这种化合物的方法，用于治疗或预防与异常或去调节激酶活性相关的疾病或障碍，特别是涉及Alk、Abl、BRK、Blk、BMX、CSK、c-Src、c-Raf、EGFR、Fes、FGFR3、Fms、Fyn、IGF-IR、IR、IKKα、IKKβ、JAK2、JAK3、KDR、Lck、Met、p70S6k、Ros、Rsk1、SAPK2α、SAPK2β、SAPK3、SIK、Tie2、TrkB和/或WNK3激酶异常激活的疾病或障碍。
• PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC A Delware Limited Liability Company

  公开号：EP1899329A1

  公开（公告）日：2008-03-19
• US8426404B2
  申请人：——

  公开号：US8426404B2

  公开（公告）日：2013-04-23
• [EN] PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE SUBSTITUÉ EN PYRIMIDINE EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：IRM LLC

  公开号：WO2007005673A1

  公开（公告）日：2007-01-11

  [EN] The invention provides, compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKKa, IKKß, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rskl, SAPK2a, SAPK2ß, SAPK3, SIK, Tie2, TrkB and/or WNK3 kinases.
  [FR] L'invention concerne des composés de formule (I), des compositions pharmaceutiques comprenant ces composés et des procédés d'utilisation desdits composés pour traiter ou prévenir des maladies ou des troubles qui sont associés à une activité anormale ou déréglée de kinases, en particulier des maladies ou des troubles impliquant une activation anormale des kinases Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKKa, IKKß, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rskl, SAPK2a, SAPK2ß, SAPK3, SIK, Tie2, TrkB et/ou WNK3.